Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study

Gaß P, Fasching P, Fehm T, De Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kuehn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Beckmann M, Wallwiener D, Kuemmel S, Löhberg C (2016)

Publication Type: Journal article

Publication year: 2016

Journal

Book Volume: 11

Pages Range: 315-322

Journal Issue: 5

DOI: 10.1159/000452468

Abstract

BACKGROUND: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. METHODS: Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. RESULTS: In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. CONCLUSION: There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Köln Germany (DE) Karl-Olga-Krankenhaus Germany (DE) Marienhospital Bottrop Germany (DE) Centrum für Hämatologie und Onkologie Bethanien Germany (DE) Eberhard Karls Universität Tübingen Germany (DE) Kliniken Essen-Mitte Germany (DE) Caritas-Krankenhaus Lebach Germany (DE) ClinSol GmbH & Co.KG Germany (DE) Martin-Luther-Universität Halle-Wittenberg (MLU) Germany (DE) Klinikum Passau Germany (DE) Städtisches Krankenhaus Kiel Germany (DE) Novartis AG Switzerland (CH) Krankenhaus Nordwest Germany (DE) Städtische Kliniken Esslingen Germany (DE) Medizinisches Zentrum Ulm Germany (DE) Evangelisches Krankenhaus Ludwigsfelde-Teltow Germany (DE) Luisenkrankenhaus Düsseldorf Germany (DE) Landkreis Mittweida Krankenhaus Germany (DE) Klinikverbund Südwest (Sindelfingen-Böblingen, Calw, Nagold, Leonberg, Herrenberg) Germany (DE) Marien-Hospital Germany (DE) Universitätsklinikum Ulm Germany (DE) Onkologische Praxis Pinneberg Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) HELIOS Kliniken Germany (DE) Klinikum Landkreis Tuttlingen Germany (DE) Elblandkliniken Germany (DE) Vinzenz-Verbund Hildesheim gGmbH Germany (DE) Kreisklinik Günzburg Krumach Germany (DE) Städtisches Klinikum Lüneburg Germany (DE) Ortenau Klinikum Germany (DE) Johanniter-Krankenhaus Genthin-Stendal Germany (DE) Klinikum Nürnberg Germany (DE) Universitätsklinikum Düsseldorf Germany (DE) Klinikum Bayreuth Germany (DE) Sana Klinikum Hameln-Pyrmont Germany (DE) Klinikum Friedrichshafen Germany (DE) Städtisches Klinikum Neunkirchen Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE)

How to cite

APA:

Gaß, P., Fasching, P., Fehm, T., De Waal, J., Rezai, M., Baier, B.,... Löhberg, C. (2016). Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care, 11(5), 315-322. https://dx.doi.org/10.1159/000452468

MLA:

Gaß, Paul, et al. "Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study." Breast Care 11.5 (2016): 315-322.

BibTeX: Download